Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: targeted activated natural killer cell therapy - ImmunityBio

Next Previous
Drug Profile

Research programme: targeted activated natural killer cell therapy - ImmunityBio

Alternative Names: CD138.taNK; CD19.taNK; CD20.taNK; CS1.taNK; EBNA3C.taNK; EpCAM.tank; GD2.taNK; GPA7.taNK; NKG2D.taNK

Latest Information Update: 28 Jul 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NantKwest
  • Developer ImmunityBio
  • Class CAR-NK cell therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 28 Jul 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
  • 28 Jul 2021 No recent reports of development identified for preclinical development in Myelodysplastic-syndromes in USA
  • 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top